polytaxel / Hyundai Biosci - LARVOL DELTA

Transforming docetaxel delivery: lung-targeted polyphosphazene nanoparticles with enhanced safety profile. (PubMed, Nanoscale) - "Polyphosphazene-docetaxel conjugate (Polytaxel, PTX) represents a rationally engineered nanomedicine designed to address the limitations of conventional taxane chemotherapy. Furthermore, in vivo metabolic profiling revealed a distinct biodegradation and clearance mechanism, with minimal generation of inactive or toxic metabolites. These results highlight the potential of PTX as a safe and effective drug delivery platform that combines enhanced therapeutic performance with reduced systemic burden, supporting its future clinical translation in cancer chemotherapy."

Journal • Oncology

Hyundai Bioscience announced on the 18th that it voluntarily withdrew its Phase 1 clinical trial plan (Investigational New Drug (IND)) for its pancreatic cancer treatment, "Polytaxel". [Google translation] (Nate) - "Hyundai Bioscience explained, 'This decision is to change the clinical design to one that considers combination administration with existing anticancer drugs, and we plan to reapply for the IND as soon as possible'."

Clinical protocol • Pancreatic Cancer

Hyundai Bio applies for phase 1 clinical trial of painless pancreatic cancer treatment 'Polytaxel' to Korea Food and Drug Administration [Google translation] (BioTimes) - "Hyundai Bioscience...announced on the 27th that it has applied to the Ministry of Food and Drug Safety for approval of a phase 1 clinical trial plan to confirm the safety and anticancer effect of Polytaxel on pancreatic cancer patients....After rapid progress in phase 1 clinical trials, it plans to proceed with phase 2/3 integrated clinical trials in the US using fast-track procedures."

New P1 trial • Pancreatic Cancer